Lowering Blood Lipids to Study Outcomes in Narrowed Brain Arteries
Tests a PCSK9 inhibitor to improve blood fat control in adults with brain artery narrowing.
Plain-language title generated from the registry record
Registry title: Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome
Key facts
- Where
- Nanjing, ChinaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate to severe intracranial artery narrowing that causes symptoms, who have high LDL cholesterol and have not had procedures inside the blood vessels.
- Age
- 18 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Moderate to severe symptomatic intracranial atherosclerotic stenosis (narrowing of an artery inside the skull).
- Earlier treatment
- Must not have had clot-dissolving drugs through a vein, clot removal, stent placement or other treatment inside the blood vessels. Must have a reason to take statins.
- Biomarker or test result
- LDL cholesterol above 70mg/dl (1.8mmol/L). Good-quality 3T MR angiography, multi-mode MR or angiography images must be available.
Main reasons for not taking part
- Cannot take statins
- Cannot have an MRI scan
- Narrowing caused by vasculitis, artery dissection or moyamoya disease
- Active bleeding or obvious bleeding tendency
- Pregnant or breastfeeding women
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT05397405, who can take part
Where in China
- Nanjing First HospitalNanjing, ChinaContact: Junshan ZhouTaking people
- Nanjing First Hospital, Nanjing Medical UniversityNanjing, ChinaContact: Junshan Zhou, M.D.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Nanjing First Hospital, Nanjing Medical University
- Trial code
- NCT05397405
- Record updated
- 15 April 2026
- Original description
sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C>1.8mmol/L) without endovascular therapy.Read full original descriptionShow less
A Prospective Observational Study on the Effect of Improving Blood Lipid Management on the Clinical Prognosis of Symptomatic Intracranial Atherosclerotic Stenosis（sICASBLM）
sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C>1.8mmol/L) without endovascular therapy.
Inclusion: Age ≥18 years; Symptomatic intracranial atherosclerotic stenosis of moderate to severe, did not receive intravenous thrombolysis, thrombectomy, stent implantation and other intravascular treatment; low density lipoprotein cholesterol > 70mg/dl (1.8mmol/L); Receive 3T magnetic resonance angiography or multi-mode MR (high resolution is required), angiography can be included, and images for analysis can be obtained; Lipid-lowering indications of statins; Signed an approved informed consents.
Exclusion: Stenosis caused by vasculitis, arterial dissection and moyamoya disease; Patients with active bleeding or obvious bleeding tendency; Severe heart, lung, renal insufficiency, malignant tumor or other malignant diseases, and death is highly likely within 7 days; pregnancy or women who are lactating; Uncontrolled severe diabetes and hypertension; Other conditions inappropriate for inclusion judged by investigators; Contraindications to statins; There are contraindications to MRI examination or cannot accept MRI examination.